Please login to the form below

Not currently logged in
Email:
Password:

Brexit

This page shows the latest Brexit news and features for those working in and with pharma, biotech and healthcare.

Time running out for ‘no-deal’ Brexit medicines laws

Time running out for ‘no-deal’ Brexit medicines laws

which would allow the MHRA to function in the even of a no deal Brexit. ... However public opinion polls show most voters - whether former 'Remain' or 'Leave' voters opposed to Theresa May's Brexit deal.

Latest news

  • Blackwood returns as new life sciences minister Blackwood returns as new life sciences minister

    Roche, Celgene, IQVIA and Oxford Biomedica. Her role also includes looking at ways in which the sector can make the most of Brexit - although the UK's pharma and biotech sector ... MPs in the House of Commons will finally have their chance to vote on the

  • NHS facing early exodus of skilled consultants NHS facing early exodus of skilled consultants

    Just 7% plan to stay after the age of 65. It’s a sobering thought in light of the staffing uncertainties posed by Brexit – particularly plans for a minimum salary threshold ... The figures come against a backdrop of uncertainty with a possible Brexit

  • EMA sees approval numbers rise in 2018 EMA sees approval numbers rise in 2018

    These were Roche’s Hemlibra, Shire’s Takhzyro, Alnylam’s Onpattro and Tegsedi. US shutdown and Brexit. ... to plan for licensing and regulatory updates, including the impact of a potential no deal Brexit.

  • Drug pricing is pharma’s top concern in 2019 Drug pricing is pharma’s top concern in 2019

    GlobalData’s poll also find that while Brexit and political uncertainty in the US were big stories in 2018, respondents viewed them as a “distant second” to drug pricing with just

  • Pharma’s confidence in Brexit deal falls as vote looms Pharma’s confidence in Brexit deal falls as vote looms

    With just a few days to go until the crucial Commons vote on Theresa May’s Brexit plan, a survey has revealed that the UK drugs industry has little confidence that ... is interesting that EMIG also reports a reduction in the proportion of members who

More from news
Approximately 112 fully matching, plus 53 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 18 fully matching, plus 23 partially matching documents found.

Latest from PMHub

  • Givers and Takers

    Noisy politicians who think Brexit is purely about what the UK wants as opposed to a win/win for everyone, impatient drivers who think their journey is more important than those

  • Artificial Intelligence in Healthcare

    Presently, the looming Brexit saga is casting shadows over the UK’s ability to play host to clinical trials at the frontiers of medical innovation.

  • What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government

    With a fresh general election less than four years away and the current government struggling to pass its Brexit plans through Parliament, the prospect of Prime Minister Jeremy Corbyn is one

  • Training the next generation of biotech leaders

    of Brexit, and how the next generation is paving the way for innovation. ... universities. With Brexit on the horizon, there is a worry that the already low number of UK scientists with expertise in cell and gene therapy will dwindle further.

  • Synergy Vision

    Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma and agency experience means that we understand our clients and can deliver bespoke medical

More from PMHub
Approximately 5 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics